Coreceptor usage in different reservoirs

Current Opinion in HIV and AIDS

Volumn 7, Issue 5, 2012, Pages 450-455

  Soulie, Cathia ^a   Calvez, Vincent ^a   Marcelin, Anne Geneviève ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

CCR5 antagonists; compartment; DNA; reservoir

Indexed keywords

CELL SURFACE PROTEIN; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; VIRUS DNA;

CD4+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CENTRAL NERVOUS SYSTEM; DISEASE COURSE; FEMALE GENITAL SYSTEM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG; MALE GENITAL SYSTEM; NONHUMAN; PEYER PATCH; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROVIRUS; REVIEW; SEXUAL TRANSMISSION; VIRAL TROPISM; VIREMIA; VIRUS CARRIER; VIRUS ENTRY; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION;

HIV-1; HUMANS; RECEPTORS, HIV; VIRAL TROPISM;

EID: 84865654912     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328356e9c2     Document Type: Review

References (96)

1. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease. Annu Rev Immunol 1999; 17:657-700.
2. Poveda E, Briz V, Quinones-Mateu M, Soriano V. HIV tropism: Diagnostic tools and implications for disease progression and treatment with entry inhibitors. AIDS 2006; 20:1359-1367.
3. Berger EA, Doms RW, Fenyo EM, et al. A new classification for HIV-1. Nature 1998; 391:240.
4. Briggs DR, Tuttle DL, Sleasman JW, GoodenowMM. Envelope V3 amino acid sequence predicts HIV-1 phenotype (co-receptor usage and tropism for macrophages). AIDS 2000; 14:2937-2939.
5. Jensen MA, van't Wout AB. Predicting HIV-1 coreceptor usage with sequence analysis. AIDS Rev 2003; 5:104-112.
6. Fouchier RA, Groenink M, Kootstra NA, et al. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992; 66:3183- 3187.
7. Bleul CC, Wu L, Hoxie JA, et al. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci U S A 1997; 94:1925-1930.
8. Lee B, Sharron M, Montaner LJ, et al. Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc Natl Acad Sci U S A 1999; 96:5215-5220.
9. Douek DC, Roederer M, Koup RA. Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med 2009; 60:471-484.
10. Brenchley JM, Schacker TW, Ruff LE, et al. CD4 T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004; 200:749-759.
11. Mehandru S, Poles MA, Tenner-Racz K, et al. Primary HIV-1 infection is associated with preferential depletion of CD4 T lymphocytes from effectorsites in the gastrointestinal tract. J Exp Med 2004; 200:761-770.
12. Kitchen SG, Zack JA. Distribution of the human immunodeficiency virus coreceptors CXCR4 and CCR5 in fetal lymphoid organs: Implications for pathogenesis in utero. AIDS Res Hum Retroviruses 1999; 15:143- 148.
13. Zhang L, He T, Talal A, et al. In vivo distribution of the human immunodeficiency virus/simian immunodeficiency virus coreceptors: CXCR4, CCR3, and CCR5. J Virol 1998; 72:5035-5045.
14. Meng G, Sellers MT, Mosteller-Barnum M, et al. Lamina propria lymphocytes, not macrophages, express CCR5 and CXCR4 and are the likely target cell for human immunodeficiency virus type 1 in the intestinal mucosa. J Infect Dis 2000; 182:785-791.
15. Moore JP, Kitchen SG, Pugach P, Zack JA. The CCR5 and CXCR4 coreceptors- central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 2004; 20:111-126.
16. Soulie C, Marcelin AG, Ghosn J, et al. HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART. AIDS 2007; 21:2243-2245.
17. Delobel P, Sandres-Saune K, Cazabat M, et al. R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2005; 38:382- 392.
18. Frange P, Galimand J, Goujard C, et al. High frequency of X4/DM-tropic viruses in PBMC samples from patients with primary HIV-1 subtype-B infection in 1996-2007: The French ANRS CO06 PRIMO Cohort Study. J Antimicrob Chemother 2009; 64:135-141.
19. Soulie C, Fourati S, Lambert-Niclot S, et al. HIV genetic diversity between plasma and cerebrospinal fluid in patients with HIV encephalitis. AIDS 2010; 24:2412-2414.
20. Soulie C, Lambert-Niclot S, Wirden M, et al. Low frequency of HIV-1 tropism evolution in patients successfully treated for at least 2 years. AIDS 2011; 25:537-539.
21. The concordance of HIV tropism determined in DNA proviral and RNA plasma is about 92% emphazing the possibility of genotypic DNA tropism determination for patients with undetectable viral load.
22. Raymond S, Delobel P, Mavigner M, et al. CXCR4-using viruses in plasma and peripheral blood mononuclear cells during primary HIV-1 infection and impact on disease progression. AIDS 2010; 24:2305-2312.
23. Paar C, Geit M, Stekel H, Berg J. Genotypic prediction of human immunodeficiency virus type 1 tropism by use of plasma and peripheral blood mononuclear cells in the routine clinical laboratory. J Clin Microbiol 2011; 49:2697-2699.
24. The genotypic prediction of HIV-1 tropism seems to be robust and suitable for routine clinical laboratory with a concordance of 90% for tropism determined both in RNA and DNA samples.
25. Verhofstede C, Brudney D, Reynaerts J, et al. Concordance between HIV-1 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA. HIV Med 2011; 12:544-552. This study demonstrated highly concordant tropism predictions for proviral DNA and plasma RNA offering a promising approach for tropism prediction in clinical practice.
26. Verhofstede C, Vandekerckhove L, Eygen VV, et al. CXCR4-using HIV type 1 variants are more commonly found in peripheral blood mononuclear cell DNA than in plasma RNA. J Acquir Immune Defic Syndr 2009; 50:126-136.
27. Abbate I, Rozera G, Tommasi C, et al. Analysis of co-receptor usage of circulating viral and proviral HIV genome quasispecies by ultra-deep pyrosequencing in patients who are candidates for CCR5 antagonist treatment. Clin Microbiol Infect 2011; 17:725-731.
28. This study evidenced the presence of minority variants with a discordant tropism in both circulating viral and proviral HIV.
29. de Mendoza C, Rodriguez C, Garcia F, et al. Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance. J Antimicrob Chemother 2007; 59:698-704.
30. Moyle GJ, Wildfire A, Mandalia S, et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005; 191:866- 872.
31. Brumme ZL, Goodrich J, Mayer HB, et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis 2005; 192:466-474.
32. Hunt PW, Harrigan PR, Huang W, et al. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis 2006; 194:926-930.
33. Poveda E, Briz V, de Mendoza C, et al. Prevalence of X4 tropic HIV-1 variants in patients with differences in disease stage and exposure to antiretroviral therapy. J Med Virol 2007; 79:1040-1046.
34. Wilkin TJ Su Z Kuritzkes DR et al. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of A CCR5 Inhibitor AIDS Clinical Trial Group A5211. Clin Infect Dis 2007; 44591-595.
35. Izopet J, Cazabat M, Pasquier C, et al. Evolution of total and integrated HIV-1 DNA and change in DNA sequences in patients with sustained plasma virus suppression. Virology 2002; 302:393-404.
36. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4 T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112-116.
37. Blaak H, van 't Wout AB, Brouwer M, et al. In vivo HIV-1 infection of CD45RACD4 T cells is established primarily by syncytium-inducing variants and correlates with the rate of CD4 T cell decline. Proc Natl Acad Sci U S A 2000; 97:1269-1274.
38. Ostrowski MA, Chun TW, Justement SJ, et al. Both memory and CD45RA/ CD62L naive CD4 T cells are infected in human immunodeficiency virus type 1-infected individuals. J Virol 1999; 73:6430-6435.
39. Philpott S, Weiser B, Anastos K, et al. Preferential suppression of CXCR4- specific strains of HIV-1 by antiviral therapy. J Clin Invest 2001; 107:431- 438.
40. Equils O, Garratty E, Wei LS, et al. Recovery of replication-competent virus from CD4 T cell reservoirs and change in coreceptor use in human immunodeficiency virus type 1-infected children responding to highly active antiretroviral therapy. J Infect Dis 2000; 182:751-757.
41. Skrabal K, Trouplin V, Labrosse B, et al. Impact of antiretroviral treatment on the tropism of HIV-1 plasma virus populations. AIDS 2003; 17:809- 814.
42. Mavigner M, Delobel P, Cazabat M, et al. HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PLoS One 2009; 4:e7658.
43. Johnston ER, Zijenah LS, Mutetwa S, et al. High frequency of syncytiuminducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment. J Virol2003; 77:7682-7688.
44. Galan I, Jimenez JL, Gonzalez-Rivera M, et al. Virological phenotype switches under salvage therapy with lopinavir-ritonavir in heavily pretreated HIV-1 vertically infected children. AIDS 2004; 18:247-255.
45. Delobel P, Nugeyre MT, Cazabat M, et al. Naive T-cell depletion related to infection by X4 human immunodeficiency virus type 1 in poor immunological responders to highly active antiretroviral therapy. J Virol 2006; 80:10229- 10236.
46. Siliciano JD, Kajdas J, Finzi D, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4 T cells. Nat Med 2003; 9:727-728.
47. Chun TW, Davey RT Jr, Engel D, et al. Re-emergence of HIV after stopping therapy. Nature 1999; 401:874-875.
48. Brenchley JM, Hill BJ, Ambrozak DR, et al. T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: Implications for HIV pathogenesis. J Virol 2004; 78:1160-1168.
49. Chun TW, Engel D, Berrey MM, et al. Early establishment of a pool of latently infected, resting CD4 T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A 1998; 95:8869-8873.
50. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 1997; 94:13193-13197.
51. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4 T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5:512-517.
52. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295- 1300.
53. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278:1291-1295.
54. Tirado G, Jove G, Reyes E, et al. Differential evolution of cell-associated virus in blood and genital tract of HIV-infected females undergoing HAART. Virology 2005; 334:299-305.
55. Philpott S, Burger H, Tsoukas C, et al. Human immunodeficiency virus type 1 genomic RNA sequences in the female genital tract and blood: Compartmentalization and intrapatient recombination. J Virol 2005; 79:353- 363.
56. Gorry PR, Bristol G, Zack JA, et al. Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity. J Virol 2001; 75:10073-10089.
57. Gorry PR, Taylor J, Holm GH, et al. Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. J Virol 2002; 76:6277-6292.
58. Peters PJ, Bhattacharya J, Hibbitts S, et al. Biological analysis of human immunodeficiency virus type 1 R5 envelopes amplified from brain and lymph node tissues of AIDS patients with neuropathology reveals two distinct tropism phenotypes and identifies envelopes in the brain that confer an enhanced tropism and fusogenicity for macrophages. J Virol 2004; 78:6915-6926.
59. Peters PJ, Duenas-Decamp MJ, Sullivan WM, Clapham PR. Variation of macrophage tropism among HIV-1 R5 envelopes in brain and other tissues. J Neuroimmune Pharmacol 2007; 2:32-41.
60. Albright AV, Shieh JT, Itoh T, et al. Microglia express CCR5, CXCR4, and CCR3, but of these, CCR5 is the principal coreceptor for human immunodeficiency virus type 1 dementia isolates. J Virol 1999; 73:205-213.
61. He J, Chen Y, Farzan M, et al. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature 1997; 385:645-649.
62. Li S, Juarez J, Alali M, et al. Persistent CCR5 utilization and enhanced macrophage tropism by primary blood human immunodeficiency virus type 1 isolates from advanced stages of disease and comparison to tissue- derived isolates. J Virol 1999; 73:9741-9755.
63. Soulie C, Tubiana R, Simon A, et al. Presence of HIV-1 R5 viruses in cerebrospinal fluid even in patients harboring R5X4/X4 viruses in plasma. J Acquir Immune Defic Syndr 2009; 51:60-64.
64. Deng H, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996; 381:661-666.
65. Dragic T, Litwin V, Allaway GP, et al. HIV-1 entry into CD4 cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381:667-673.
66. Ohagen A, Ghosh S, He J, et al. Apoptosis induced by infection of primary brain cultures with diverse human immunodeficiency virus type 1 isolates: Evidence for a role of the envelope. J Virol 1999; 73:897-906.
67. Ellis RJ, Gamst AC, Capparelli E, et al. Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources. Neurology 2000; 54:927- 936.
68. Haas DW, Clough LA, Johnson BW, et al. Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma. AIDS Res Hum Retroviruses 2000;16:1491-1502.
69. Parisi SG, Andreoni C, Sarmati L, et al. HIV coreceptor tropism in paired plasma, peripheral blood mononuclear cell, and cerebrospinal fluid isolates from antiretroviral-naive subjects. J Clin Microbiol 2011; 49:1441- 1445.The HIV tropism in cerebrospinal fluid was mainly R5 for antiretroviral-naíve patients.
70. Feng G Hannan F Reale V et al. Cloning functional characterization of a Novel Dopamine Receptor From Drosophila Melanogaster. J Neurosci 1996; 163925-3933.
71. Kemal KS, Foley B, Burger H, et al. HIV-1 in genital tract and plasma of women: Compartmentalization of viral sequences, coreceptor usage, and glycosylation. Proc Natl Acad Sci U S A 2003; 100:12972-12977.
72. Ellerbrock TV, Lennox JL, Clancy KA, et al. Cellular replication of human immunodeficiency virus type 1 occurs in vaginal secretions. J Infect Dis 2001; 184:28-36.
73. Sullivan ST, Mandava U, Evans-Strickfaden T, et al. Diversity, divergence, and evolution of cell-free human immunodeficiency virus type 1 in vaginal secretions and blood of chronically infected women: Associations with immune status. J Virol 2005; 79:9799-9809.
74. Andreoletti L, Skrabal K, Perrin V, et al. Genetic and phenotypic features of blood and genital viral populations of clinically asymptomatic and antiretroviral- treatment-naive clade a human immunodeficiency virus type 1-infected women. J Clin Microbiol 2007; 45:1838-1842.
75. Poss M, Rodrigo AG, Gosink JJ, et al. Evolution of envelope sequences from the genital tract and peripheral blood of women infected with clade A human immunodeficiency virus type 1. J Virol 1998; 72:8240-8251.
76. Zhu T, Wang N, Carr A, et al. Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: Evidence for viral compartmentalization and selection during sexual transmission. J Virol 1996; 70:3098-3107.
77. Kelly KA, Rank RG. Identification of homing receptors that mediate the recruitment of CD4 T cells to the genital tract following intravaginal infection with Chlamydia trachomatis. Infect Immun 1997; 65:5198-5208.
78. Olive AJ, Gondek DC, Starnbach MN. CXCR3 and CCR5 are both required for T cell-mediated protection against C. trachomatis infection in the murine genital mucosa. Mucosal Immunol 2011; 4:208-216.
79. Wolfs TF, Zwart G, Bakker M, Goudsmit J. HIV-1 genomic RNA diversification following sexual and parenteral virus transmission. Virology 1992; 189:103- 110.
80. Zhu T, Mo H, Wang N, et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993; 261:1179-1181.
81. van 't Wout AB, Kootstra NA, Mulder-Kampinga GA, et al. Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J Clin Invest 1994; 94:2060-2067.
82. Hladik F, Lentz G, Delpit E, et al. Coexpression of CCR5 and IL-2 in human genital but not blood T cells: Implications for the ontogeny of the CCR5 Th1 phenotype. J Immunol 1999; 163:2306-2313.
83. Veazey RS, DeMaria M, Chalifoux LV, et al. Gastrointestinal tract as a major site of CD4 T cell depletion and viral replication in SIV infection. Science1998; 280:427-431.
84. Guadalupe M, Reay E, Sankaran S, et al. Severe CD4 T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol 2003; 77:11708-11717.
85. Anton PA, Elliott J, Poles MA, et al. Enhanced levels of functional HIV-1 coreceptors on human mucosal T cells demonstrated using intestinal biopsy tissue. AIDS 2000; 14:1761-1765.
86. Poles MA, Elliott J, Taing P, et al. A preponderance of CCR5() CXCR4() mononuclear cells enhances gastrointestinal mucosal susceptibility to human immunodeficiency virus type 1 infection. J Virol 2001; 75:8390-8399.
87. Olsson J, Poles M, Spetz AL, et al. Human immunodeficiency virus type 1 infection is associated with significant mucosal inflammation characterized by increased expression of CCR5, CXCR4, and beta-chemokines. J Infect Dis 2000; 182:1625-1635.
88. van Marle G, Gill MJ, Kolodka D, et al. Compartmentalization of the gut viral reservoir in HIV-1 infected patients. Retrovirology 2007; 4:87.
89. Chun TW, Nickle DC, Justement JS, et al. Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis 2008; 197:714-720.
90. Imamichi H, Degray G, Dewar RL, et al. Lack of compartmentalization of HIV-1 quasispecies between the gut and peripheral blood compartments. J Infect Dis 2011; 204:309-314.
91. This study provided evidence of ongoing virus production in the gut and equilibrium of HIV between the gut and peripheral blood compartments. 88. Fels AO, Cohn ZA. The alveolar macrophage. J Appl Physiol 1986; 60:353- 369.
92. Itescu S, Simonelli PF, Winchester RJ, Ginsberg HS. Human immunodeficiency virus type 1 strains in the lungs of infected individuals evolve independently from those in peripheral blood and are highly conserved in the C-terminal region of the envelope V3 loop. Proc Natl Acad Sci U S A 1994; 91:11378-11382.
93. Schuitemaker H, Koot M, Kootstra NA, et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-celltropic virus population. J Virol 1992; 66:1354-1360.
94. Singh A, Besson G, Mobasher A, Collman RG. Patterns of chemokine receptor fusion cofactor utilization by human immunodeficiency virus type 1 variants from the lungs and blood. J Virol 1999; 73:6680- 6690.
95. Nakata K, Weiden M, Harkin T, et al. Low copy number and limited variability of proviral DNA in alveolar macrophages from HIV-1-infected patients: Evidence for genetic differences in HIV-1 between lung and blood macrophage populations. Mol Med 1995; 1:744-757.
96. Heath L, Fox A, McClure J, et al. Evidence for limited genetic compartmentalization of HIV-1 between lung and blood. PLoS One 2009; 4:e6949.